Lyra Therapeutics (LYRA) Capital Expenditures (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Capital Expenditures of $96000.0 in Q4 2025, up 265.52% on a QoQ basis from -$58000.0 in Q4 2024, and up 265.52% YoY from $26264.2 in Q4 2024.
Lyra Therapeutics (LYRA) Capital Expenditures (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Capital Expenditures for 7 consecutive years, with $96000.0 the latest figure, recorded in Q4 2025.
- Capital Expenditures for Q4 2025 came in at $96000.0, up 265.52% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (up 1.37% YoY), and the FY2025 annual result was $116000.0, down 95.04% from the prior year.
- Capital Expenditures for Q4 2025 stood at $96000.0, up from -$58000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $2.3 million in Q3 2024, with the low at -$2.1 million in Q2 2024.
- A 5-year average of $191882.4 and a median of $93000.0 in 2022 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 14400.0% in 2021 and tumbled 3036.62% in 2024, its largest moves.
- Lyra Therapeutics' Capital Expenditures stood at -$1.0 million in 2021, then soared by 102.78% to $28000.0 in 2022, then surged by 1196.43% to $363000.0 in 2023, then slumped by 115.98% to -$58000.0 in 2024, then surged by 265.52% to $96000.0 in 2025.
- The last three Capital Expenditures figures came in at $96000.0 (Q4 2025), -$58000.0 (Q4 2024), and $2.3 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 96,000.00 |
| Dec 31, 2025 | 96,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Sep 30, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | -2.09 Mn |
| Jun 30, 2024 | -2.09 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 363,000.00 |
| Dec 31, 2023 | 363,000.00 |
| Sep 30, 2023 | 144,000.00 |
| Sep 30, 2023 | 144,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Dec 31, 2022 | 28,000.00 |